Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Trial Profile

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs Cixutumumab (Primary) ; Everolimus; Octreotide
  • Indications Adenocarcinoma; Gastrointestinal cancer; Glucagonoma; Insulinoma; Neuroendocrine carcinoma; Pancreatic cancer; Paraganglioma; Thyroid cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 11 May 2016 Status changed from discontinued to completed.
    • 29 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top